skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study

Original Research

(3996) Views  (910) Full article downloads

Authors: Giray Kabakci, Nevres Koylan, Baris Ilerigelen, Omer Kozan, Kemalettin Buyukozturk on behalf of the ICEBERG Investigators

Published Date November 2008 Volume 2008:1 Pages 5 - 13
DOI: http://dx.doi.org/10.2147/IBPC.S3809

Giray Kabakci1, Nevres Koylan2, Baris Ilerigelen3, Omer Kozan4, Kemalettin Buyukozturk2 on behalf of the ICEBERG Investigators

1Hacettepe University, Hacettepe School of Medicine, Department of Cardiology, Ankara, Turkey; 2Istanbul University, Istanbul School of Medicine, Department of Cardiology, Istanbul, Turkey; 3Istanbul University, Cerrahpasa School of Medicine, Department of Cardiology, Istanbul, Turkey; 4Dokuz Eylul University, Dokuz Eylul School of Medicine, Department of Cardiology, Izmir, Turkey

Background: Hypertension, dyslipidemia, and other cardiovascular risk factors are linked epidemiologically, clinically, and metabolically. Intensive/Initial Cardiovascular Examination regarding Blood Pressure levels, Evaluation of Risk Groups (ICEBERG) study focuses on the effect of dyslipidemia on cardiovascular risk evaluation and association of lipid profile with other risk factors.

Patients and methods: The ICEBERG study consisted of two sub-protocols: ICEBERG-1, conducted at 20 university hospitals (Referral Group) and ICEBERG-2, conducted at 197 primary healthcare centers (Primary Care Group). Sub-protocol had two patient profiles: patients previously diagnosed with essential hypertension and under medical treatment (Treated Group) and patients with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg, with no antihypertensive treatment for at least 3 months before inclusion (Untreated Group). Dyslipidemia was evaluated and cardiovascular risk stratification was performed according to ESC/ESH guidelines.

Results: More than half of the treated and untreated subjects were classified into high or very high cardiovascular risk groups. In a total of 1817 patients, the percentage of patients in “high” plus “very high” added risk groups increased to 55.2% in Treated Referral Group (p < 0.001), to 62.6% in Untreated Referral Group (p = 0.25) and to 60.7% in Untreated Primary Care Group (p < 0.001), by re-evaluation of patients’ lipid values.

Conclusions: Serum lipid levels are useful in stratifying hypertensive patients into cardiovascular risk groups more accurately, for appropriate antihypertensive treatment.

Keywords: hypertension, dyslipidemia, cardiovascular disease








Readers of this article also read:

Study of the intima-media thickening in carotid arteries of healthy elderly with high blood pressure and elderly with high blood pressure and dyslipidemia
Antihypertensive effects of astaxanthin
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia
Venous and arterial thrombosis: Two aspects of the same disease?
Clinical approach in treatment of resistant hypertension
Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University